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ABSTRACT
Background: Atypical melanocytic tumors (AMTs) include a wide
spectrum of melanocytic neoplasms that represent a challenge for
clinicians due to the lack of a definitive diagnosis and the related
uncertainty about their management. This study analyzed clinico-
pathologic features and sentinel node status as potential prognostic
factors in patients with AMTs. Patients and Methods: Clinicopath-
ologic and follow-up data of 238 children, adolescents, and adults
with histologically proved AMTs consecutively treated at 12 Euro-
pean centers from 2000 through 2010 were retrieved from pro-
spectively maintained databases. The binary association between all
investigated covariates was studied by evaluating the Spearman
correlation coefficients, and the association between progression-
free survival and all investigated covariates was evaluated using
univariable Cox models. The overall survival and progression-free
survival curves were established using the Kaplan-Meier method.
Results: Median follow-up was 126 months (interquartile range,
104–157 months). All patients received an initial diagnostic biopsy
followed by wide (1 cm) excision. Sentinel node biopsy was per-
formed in 139 patients (58.4%), 37 (26.6%) of whom had sentinel
node positivity. There were 4 local recurrences, 43 regional relapses,
and 8 distant metastases as first events. Six patients (2.5%) died of
disease progression. Five patients who were sentinel node–negative
and 3 patients who were sentinel node–positive developed distant
metastases. Ten-year overall and progression-free survival rates were
97% (95% CI, 94.9%–99.2%) and 82.2% (95% CI, 77.3%–87.3%), re-
spectively. Age, mitotic rate/mm2, mitoses at the base of the lesion,
lymphovascular invasion, and 9p21 loss were factors affecting
prognosis in the whole series and the sentinel node biopsy subgroup.
Conclusions: Age .20 years, mitotic rate .4/mm2, mitoses at the
base of the lesion, lymphovascular invasion, and 9p21 loss proved to
be worse prognostic factors in patients with ATMs. Sentinel node
status was not a clear prognostic predictor.
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Background
Cutaneous melanocytic lesions represent a wide spec-
trum, ranging from benign to overtly malignant. This
composite group includes atypical melanocytic tumors
(AMTs), mostly occurring in children, adolescents, and
young adults,1,2 whose biologic behavior and meta-
static risk have been controversial and difficult to
predict since their initial description by Spitz.1 In fact,
these tumors have some attributes of malignancy, such
as cytologic atypia and mitotic activity, that are con-
sidered of insufficient severity to justify a diagnosis of
frank malignancy. They were later defined as “borderline
melanomas”3,4 or “minimal deviation melanomas”5–7
because of the interpretative problems they presented
to physicians in distinguishing them from benign
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melanocytic nevi. Smith et al8 and Barnhill et al,9 in dif-
ferent analyses, described a kind of Spitz nevus showing
atypia and the capability of metastasizing, and they
classified this neoplasm as Spitz tumor or atypical Spitz
tumor. In subsequent studies, Barnhill10 and Elder and
Xu11 introduced the term “melanocytic tumor of uncertain
malignant potential” or “melanocytic proliferation with
indeterminate biologic potential,” a descriptive diagnosis
generally accompanied by a differential diagnosis, to
underline the uncertainties in predicting the clinical be-
havior. Cerroni et al12 studied a series of melanocytic
tumors of uncertain malignant potential and found that
the presence of increasedmitotic activity,mitoses near the
base of the lesion, and an inflammatory reaction were
statistically significant parameters unfavorably affecting
outcome.
To integrate the conventional morphologic assess-
ment methods for these difficult lesions, some authors
proposed sentinel node (SN) status assessment (negative
vs positive).13,14 The MSLT-1 trial demonstrated the
utility of sentinel node biopsy (SNB) as a staging tool and
found that SN status was the most powerful prognostic
factor in patients with melanoma; this trial was the
primary reference study supporting the use of SNB in
cutaneous melanoma.15 The rationale behind the use of
SNB also in AMT was the assumption that the detection
of melanocytic cells in the draining regional lymph node
basin generally indicates malignancy.14
Although some authors found that SN status did not
seem to be useful in predicting outcome in atypical
spitzoid tumors, a subset of AMT generally occurring in
young patients and associated with a good prognosis,
other studies emphasized the possible diagnostic and
prognostic role of SN status in AMTs, particularly in older
patients and nonspitzoid lesions.16–18 In different anal-
yses, Gerami et al19,20 and Shen et al21 showed that the
integration of molecular and histopathologic data im-
proved the risk assessment of spitzoid tumors, and the
use of fluorescence in situ hybridization (FISH) has
suggested that specific genomic alterations affect the
prognosis of atypical spitzoid tumors. Because the few
published analyses of AMT are limited by the small series
of cases and/or short follow-up,22,23 further character-
ization of these lesions could be of relevance. We
therefore analyzed a large series of patients with a long
follow-up to better define the role of SN status as a
prognostic factor and to identify other potential clini-
copathologic predictors of survival.
Patients and Methods
Clinicopathologic Features and FISH Analysis
A total of 238 patients eligible for the study analysis
were consecutively treated from 2000 through 2010 at
the Istituto Nazionale dei Tumori, Milan, University Hos-
pitals of Brescia, Modena, Parma, and Pavia, and General
Hospitals of Cremona, Macerata, Siracusa, and Trapani,
all in Italy; Istituto Oncologico Svizzera Italiana, Ospe-
dale Regionale Bellinzona e Valli, Bellinzona, Switzer-
land; University Hospital of Heraklion, Greece; and
Queen Mary University, London, United Kingdom.
Clinicopathologic data were retrieved from prospectively
maintained databases. All cases were reviewed in-
dependently by a pool of dermatopathologists (B.V.,
M.C., M.B., A.P., S.L.P.), with disagreements resolved
through discussion. Cases were subcategorized into 2
groups: spitzoid and nonspitzoid. Spitzoid tumors had a
morphology resembling a Spitz tumor (largemelanocytic
cells, spindle cells and/or epithelioid cells, sharp lateral
demarcation of the nests of intraepidermal melanocytes,
maturity of cells, and rarity of individual melanocytes
high above the basal cell layer).12,24 Nonspitzoid tumors
included nevoid lesions (resembling a conventional or
dysplastic nevus), pigmented epithelioid melanocyto-
mas, deep penetrating nevi, and atypical blue nevi.12
Patient age and sex, histologic subtype, tumor thickness,
ulceration, mitotic rate (MR)/mm2, presence of mitotic
figures at the base of the lesion (marginal mitoses, within
0.25 mm of the dermal margin of the lesion),25 lym-
phovascular invasion (LVI), and tumor-infiltrating lym-
phocytes were recorded for all cases. Morphologic and
FISH analysis provided support for a diagnosis of AMT
according to the WHO classification criteria.26 Two hy-
bridizations were performed: the 4-probe FISH assay
targeting 6p25, 6q23, 11q13, and Cep6 was used for the
first hybridization, and the 4-probe FISH assay targeting
6p25, 9p21, 11q13, and 8q24 was used for the second.19,20
The pool of dermatopathologists, having experience in
molecular diagnostics and FISH testing, performed the
FISH analyses. A patient was considered to have a pos-
itive FISH result based on the criteria and cutoff values
used by Gerami et al.19,20,27 All patients received an initial
diagnostic biopsy followed by wide (1 cm) excision; SNB
was performed in 139 patients (58.4%) after the benefits
and potential harms had been discussed with them. A
total of 95 patients eligible for SNB declined the pro-
cedure, whereas 4 did not undergo it due to the presence
of comorbidities. Pathologic assessment of SNs was
performed according to the EORTC protocol.28 Patients
with positive SNs were offered completion lymph node
dissection (CLND) as additional therapy.
Statistical Methods
Clinicopathologic characteristics were recorded according
to SNB (performed vs not performed) for the whole series
of patients, according to SN status (positive vs negative) in
the group undergoing SNB, and according to CLND
(performed vs not performed) in the SN-positive group.
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The primary endpoints of the study were overall survival
(OS) and progression-free survival (PFS). The OS and PFS
curves were estimated using the Kaplan-Meier method29
and compared using the log-rank test. Inverse probability
of treatment weighting (IPTW)30 was applied to groups
affected by a selection bias. Standardizedmean difference
(SMD)31 was used to evaluate the balancing of clinico-
pathologic characteristics. The association between PFS
and all investigated covariates was assessed via uni-
variable Cox models.
We applied the elastic net penalization method in
the Cox model to perform covariate selection for PFS
between all investigated features in the SNB subgroup.32
More details on the statistical methods are provided in
the supplemental eAppendix 1 (available with this article
at JNCCN.org).
Results
Patient and Disease Characteristics
Clinicopathologic characteristics of the 238 patients with
a diagnosis of AMT are summarized in Table 1. Patient
age ranged from 3 to 53 years; most AMTs (52.5%) were
diagnosed in young patients (age #20 years). The most
frequent primary site was the lower limbs (38.2%).
Spitzoid tumors numbered 81 (34%); nonspitzoid tumors
numbered 157 (66%) and included nevoid lesions (n589;
37.4%), pigmented epithelioid melanocytomas (n519;
8%), deep penetrating nevi (n543; 18.1%), and atypical
blue nevi (n56; 2.5%).Mitoses at the base of the lesion and
LVI were detected in 29% and 23.5% of cases, respectively.
In 28.6% of cases, the FISH test showed 9p21 loss.
Clinicopathologic characteristics of the 238 patients
according to SNB are summarized in Table 2. The group
that underwent SNB and the non-SNB group did not
differ with respect to sex, tumor site, tumor thickness,
ulceration, MR/mm2, and tumor-infiltrating lympho-
cytes. The SNB group differed significantly from the non-
SNB group in age (5.8% vs 38.4% aged#10 years; 23.0% vs
47.5% aged 11–20 years; and 71.2% vs 14.1% aged.20 years).
Histologic subtype differed in the SNB group compared
with the non-SNB group: 75.5% of patients who un-
derwent SNB had nonspitzoid tumors and 24.5% had
spitzoid lesions; among those in the non-SNB group,
52.5% had nonspitzoid tumors and 47.5% spitzoid lesions.
The group that underwent SNB showed significantly
higher rates of mitoses at the base of the lesion (33.8% vs
22.2%), LVI (28.1% vs 17.2%), and 9p21 loss (33.8% vs
21.2%) than the non-SNB group.
Of the 139 patients that underwent SNB and the 99
that did not, 55 (39.6%) and 26 (26.3%), respectively,
showed FISH abnormalities. SNB revealed metastatic
involvement in 37 (26.6%) patients. Clinicopathologic
characteristics of the 139 patients according to SN status
are summarized in supplemental eTable 1. Patients who
were SN-positive significantly differed from those who
were SN-negative in median number of mitoses/mm2 (5
vs 2, respectively; SMD, 1.946), presence of mitoses at the
base of the lesion (86.5% vs 14.7%, respectively; SMD,
2.062), and LVI (75.7% vs 10.8%; SMD, 1.733). Patients
who were SN-positive showed significantly higher rates
of 9p21 loss than those who were SN-negative (45.9% vs
29.4%; SMD, 1.587). Of the 37 patients who were SN-
positive, 19 (51.4%) showed FISH abnormalities; 21
(56.7%) of 37 underwent CLND, among whom 1 (4.8%)
showed further positive non-SNs. Patients who were SN-
positive were not offered further treatment (ie, systemic
therapies) other than CLND. After IPTW, SMD reached
values ,0.1 for all covariates included in the propensity
score model.
Survival Analysis
Median follow-up was 126 months (interquartile range,
104–157 months). The 10-year OS and PFS were 97%
(95% CI, 94.9%–99.2%) and 82.2% (95% CI, 77.3%–87.3%),
respectively (Figure 1). The group that did not undergo
SNB showed slightly better 10-year OS and PFS proba-
bilities than the group that did: 100% versus 94.9% (95%
CI, 91.3%–98.7%) and 87.8% (95% CI, 81.6%–94.5%)
versus 77.9% (95% CI, 71.0%–85.4%), respectively
(Figure 2A, C). Weighted comparisons showed that 10-
year OS and PFS were 100% versus 96.8% (95% CI,
93.3%–100%) and 88.5% (95% CI, 82.4%–95.1%) versus
84.6% (95% CI, 77.4%–92.4%), respectively; these dif-
ferences were not statistically significant (Figure 2B,
D). Patients who were SN-negative and those who were
SN-positive had similar 10-year OS (96.0% [95% CI,
92.3%–99.9%] vs 91.9% [95% CI, 83.5%–100%]; P5.332),
whereas patients who were SN-negative showed higher
10-year PFS (84.2% [95% CI, 77.4%–91.6%] vs 63.6% [95%
CI, 49.6%–81.7%]; P5.045) (supplemental eFigure 1).
Supplemental eTable 2 summarizes the clinicopath-
ologic characteristics of patients who were SN-positive
according to CLND before and after propensity score
weighting. Patients undergoing CLND showed observed
10-year OS and PFS probabilities similar to those of
patients who did not undergo the procedure: 90.5% (95%
CI, 78.8%–100%) versus 93.8% (95% CI, 82.6%–100%) and
61.0 (95% CI, 43.0%–86.3%) versus 67.0% (95% CI,
46.9%–95.8%), respectively (supplemental eFigure 2A, C).
After weighting, the 10-year OS and PFS probabilities
were 85.8% (95% CI, 65.6%–100%) versus 97.9% (95% CI,
89.0%–100%) and 64.9% (95% CI, 39.6%–100%) versus
61.0% (95% CI, 35.7%–100%), respectively (supplemental
eFigure 2B, D).
There were 4 local recurrences, 43 regional recur-
rences, and 8 distant metastases as first events. Six pa-
tients died as a result of disease progression. Of the
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patients who developed regional recurrences, 34 (79.1%)
had not undergone SNB, 6 (13.9%) underwent SNB and
were SN-positive, and 3 (7%) underwent SNB and were
SN-negative. Of the 51 patients who developed regional
and distant metastases, 40 (78.4%) showed FISH ab-
normalities. Five patients who were SN-negative and 3
who were SN-positive, all belonging to the nonspitzoid
group, developed distant metastases beyond the regional
nodal basin; of these patients, 4 developed distant me-
tastases after regional recurrence and 4 had distant
spread in the absence of previous regional node metas-
tases. The 8 patients who developed distant disease—6 of
whom died of their disease—had an age range from 28 to
42 years; the histologic diagnosis was nevoid lesion in 6
cases, deep penetrating nevus in 1 case, and atypical blue
nevus in 1 case. Three patients developed another ma-
lignancy, and 1 died of causes unrelated to AMT.
In univariable analysis of the whole series, age #10
versus .20 years and age 11–20 versus .20 years; MR
$4/mm2; mitoses at the base of the lesion; LVI; and 9p21
loss (all P,.001) were strongly associated with a worse
PFS, whereas SN status (P5.024) was mildly associated.
All of the strongly associated variables were observed in
the group in which SNB was performed (Table 3). The
hazard ratio of PFS increased from 0 to 4 for MR and then
reached a plateau, whereas for age, it increased up to 30
years and then decreased. Among the 55 patients with
recurrences, 37 (67.3%) had MR $4, 35 (63.6%) had
mitoses at the base of the lesion, 33 (60%) had LVI, and 34
(61.8%) showed 9p21 loss. Of the 183 patients without
recurrences 21 (11.5%) had MR $4, 19 (10.4%) had mi-
toses at the base of the lesion, 24 (13.1%) had LVI, and 26
Table 1. Clinicopathologic Characteristics
Characteristic n (%)
Total 238 (100)
Age
#10 y 46 (19.3)
11–20 y 79 (33.2)
.20 y 113 (47.5)
Sex
Female 122 (51.3)
Male 116 (48.7)
Tumor site
Head and neck 78 (32.8)
Upper limbs 43 (18.1)
Trunk 26 (10.9)
Lower limbs 91 (38.2)
Histologic subtype
Spitzoid 81 (34.0)
Nonspitzoida 157 (66.0)
Tumor thickness, mm
Median (IQRE) 2.34 (2.20–2.49)
Ulceration
Absent 225 (94.5)
Present 13 (5.5)
Mitosis, per mm2
Median (IQRE) 2 (1–4)
Mitosis at the base of the lesion
Absent 169 (71.0)
Present 69 (29.0)
Lymphovascular invasion
Absent 182 (76.5)
Present 56 (23.5)
Tumor-infiltrating lymphocytes
Absent 83 (34.9)
Brisk 79 (33.2)
Nonbrisk 76 (31.9)
FISH test 6p25
Negative 209 (87.8)
Positive 29 (12.2)
FISH test 6q23/Cep 6
Negative 231 (97.1)
Positive 7 (2.9)
FISH test 6p25/Cep 6
Negative 233 (97.9)
Positive 5 (2.1)
(continued)
Table 1. Clinicopathologic Characteristics (cont.)
Characteristic n (%)
FISH test 11q13
Negative 211 (88.7)
Positive 27 (11.3)
FISH test 9p21
Negative 170 (71.4)
Positive 68 (28.6)
FISH test 8q24
Negative 234 (98.3)
Positive 4 (1.7)
Sentinel node biopsy
Negative 102 (42.9)
Positive 37 (15.5)
Not performed 99 (41.6)
Abbreviation: FISH, fluorescence in situ hybridization; IQRE, interquartile range
extremes.
aNevoid, deep penetrating nevus, or atypical blue nevus.
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Table 2. Clinicopathologic Characteristics According to SNB, Before and After Propensity Score Weighting
Unweighted Statistics Weighted Statistics
SNB Not Performed
n (%)
SNB Performed
n (%) SMD
SNB Not Performed
n (%)
SNB Performed
n (%) SMD
Total 99 (41.6) 139 (58.4) 96.4 (50.8) 96.1 (49.2)
Age 0.160 0.005
#10 y 38 (38.4) 8 (5.8) 37.2 (38.6) 37.5 (39.0)
11–20 y 47 (47.5) 32 (23.0) 46.1 (47.8) 48.4 (50.4)
.20 y 14 (14.1) 99 (71.2) 13.1 (13.6) 10.2 (10.6)
Sex 0.026 0.016
Female 51 (51.5) 71 (51.1) 50.3 (52.2) 50.9 (53)
Male 48 (48.5) 68 (48.9) 46.1 (47.8) 45.2 (47)
Tumor site 0.230 0.067
Head and neck 34 (34.3) 44 (31.7) 32.7 (33.9) 33.8 (35.2)
Upper limbs 17 (17.2) 26 (18.7) 16.5 (17.1) 17.1 (17.8)
Trunk 10 (10.1) 16 (11.5) 10.0 (10.4) 7.2 (7.5)
Lower limbs 38 (38.4) 53 (38.1) 37.2 (38.6) 38.0 (39.5)
Histologic subtype 0.049 0.078
Spitzoid 47 (47.5) 34 (24.5) 46.3 (48.0) 44.8 (46.6)
Nonspitzoida 52 (52.5) 105 (75.5) 50.1 (52.0) 51.3 (53.4)
Tumor thickness, mm 0.056 0.007
Median (IQRE) 2.32 (2.21–2.50) 2.35 (2.22–2.49) 2.32 (2.20–2.50) 2.35 (2.25–2.48)
Ulceration 0.031 0.021
Absent 94 (94.9) 131 (94.2) 91.4 (94.8) 91.6 (95.3)
Present 5 (5.1) 8 (5.8) 5 (5.2) 4.5 (4.7)
Mitosis, per mm2 0.218 0.002
Median (IQRE) 2 (1–2) 2 (1–5) 2 (1–2) 2 (1–2)
Mitosis at the base of the lesion 0.260 0.001
Absent 77 (77.8) 92 (66.2) 75.4 (78.2) 75.2 (78.3)
Present 22 (22.2) 47 (33.8) 21 (21.8) 20.9 (21.7)
Lymphovascular invasion 0.262 0.001
Absent 82 (82.8) 100 (71.9) 79.4 (82.4) 79.1 (82.3)
Present 17 (17.2) 39 (28.1) 17 (17.6) 17.0 (17.7)
Tumor-infiltrating lymphocytes 0.155 0.141
Absent 38 (38.4) 45 (32.4) 37.3 (38.7) 32.1 (33.4)
Brisk 29 (29.3) 50 (36.0) 27.4 (28.5) 33.2 (34.5)
Nonbrisk 32 (32.3) 44 (31.7) 31.6 (32.8) 30.8 (32.1)
FISH test 6p25 0.110 0.072
Negative 89 (89.9) 120 (86.3) 86.6 (89.9) 88.4 (92.0)
Positive 10 (10.1) 19 (13.7) 9.8 (10.1) 7.7 (8.0)
FISH test 6q23/Cep 6 0.096 0.105
Negative 96 (97.0) 135 (97.1) 93.4 (96.9) 93.4 (97.2)
Positive 3 (3.0) 4 (2.9) 3.0 (3.1) 2.7 (2.8)
FISH test 6p25/Cep 6 0.136 0.136
Negative 97 (98.0) 136 (97.8) 94.4 (97.9) 92.2 (95.9)
Positive 2 (2.0) 3 (2.2) 2.0 (2.1) 3.9 (4.1)
(continued on next page)
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(14.2%) showed 9p21 loss. After IPTW, SMD reached
values ,0.1 for all covariates included in the PS model
(data not shown).
Predictive Covariate Selection
The elastic net penalized Cox model selection procedure
led to the selection of higher MR, mitoses at the base of
the lesion, LVI, and 9p21 loss as the most relevant
covariates for PFS prediction. The sparsity of the events
and the high correlation issue in our series prevented us
from developing a reliable predictive model based on the
selected variables.
Discussion
We found a positive SN rate of 26.6%, in line with data
reported in other studies in which a higher proportion of
positive SNs was observed in patients with AMTs com-
pared with those with conventional melanomas.15,33
However, our study did not clearly show that SN status
was a predictor of OS. Although most of the variables
associated with a worse prognosis (MR/mm2 $4, mitoses
at the base of the lesion, LVI, and 9p21 loss) were prevalent
in patients whowere SN-positive and could be considered
to identify individuals eligible for SNB, in our analyses, SN
status did not seem to provide the same important
prognostic information for AMT as observed in cutaneous
melanoma.15 Because our findings are not strong enough
to mandate SNB for AMT currently, ultrasound imaging
could be an alternative approach during follow-up.34
However, the number of positive SNs in our series was
small, and further analyses of larger series of patients are
needed to better evaluate the prognostic role of SN status.
Previous studies in small series with a shorter follow-
up focusing on the role of SN status yielded controversial
results. Busam et al35 reported that children and teen-
agers with spitzoid AMTs and positive SNs had a less
aggressive clinical course than patients with SN-positive
melanoma. Ghazi et al,16 in a study of patients with AMTs
with a median age of 24 years, showed that lymph node
assessment did not predict the outcome of spitzoid
AMTs. Gamblin et al36 and Murali et al,37 in different
analyses, reached the opposite conclusion, arguing that
SNB could offer a means for assessing the metastatic
potential of spitzoid AMTs and represented an adjunct
tool in patient management.
In our series, the 6 deaths as a result of disease
progression confirmed that AMT should be considered a
provisional diagnosis pending molecular and genetic
analyses, expert review, and outcome; all our data were
used to predict the likelihood of melanoma in these pa-
tients. Our analysis showed thatMR$4 and the presence of
mitoses at the base of the lesion correlated with a worse
prognosis. These factors seemed to be indicators of a more
aggressive clinical behavior and to be associated with a
higher probability of distant metastatic spread beyond the
regional nodal basin. Mitosis should be taken into con-
sideration as a prognostic factor in AMTs, and its relevance
should be carefully evaluated in clinical decision-making.
Table 2. Clinicopathologic Characteristics According to SNB, Before and After Propensity Score Weighting
(cont.)
Unweighted Statistics Weighted Statistics
SNB Not Performed
n (%)
SNB Performed
n (%) SMD
SNB Not Performed
n (%)
SNB Performed
n (%) SMD
FISH test 11q13 0.680 0.030
Negative 89 (89.9) 122 (87.8) 86.6 (89.9) 85.5 (88.9)
Positive 10 (10.1) 17 (12.2) 9.8 (10.1) 10.6 (11.1)
FISH test 9p21 0.285 0.001
Negative 78 (78.8) 92 (66.2) 75.4 (78.2) 75.2 (78.3)
Positive 21 (21.2) 47 (33.8) 21 (21.8) 20.9 (21.7)
FISH test 8q24 0.092 0.114
Negative 97 (98.0) 137 (98.6) 94.4 (97.9) 92.7 (96.5)
Positive 2 (2.0) 2 (1.4) 2.0 (2.1) 3.4 (3.5)
SNB — —
Negative 0 (0.0) 102 (73.4) 0 (0) 77.6 (80.7)
Positive 0 (0.0) 37 (26.6) 0 (0) 18.5 (19.3)
Not performed 99 (100) 0 (0.0) 96.4 (100) 0 (0)
Abbreviations: AMT, atypical melanocytic tumor; FISH, fluorescence in situ hybridization; IQRE, interquartile range extremes; SMD, standardized mean difference;
SNB, sentinel node biopsy.
aNevoid, deep penetrating nevus, or atypical blue nevus.
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Our data are in line with various previous reports in
which these variables were heavily weighted for their
diagnostic and prognostic significance. Cerroni et al12
identified only 3 parameters that were statistically
different between 2 groups of AMTs with favorable
and unfavorable behavior based on clinical follow-
up: high MR, mitoses near the base of the lesion, and
an inflammatory infiltrate. In a more recent study,
Gerami et al38 assessed interobserver agreement in
diagnosis by 13 expert dermatopathologists for 75
atypical spitzoid tumors and confirmed that frequent
mitoses and deep mitoses were histomorphologic
features that correlated with disease progression. In
our analysis, no statistically significant association
was found between an inflammatory infiltrate and
patient outcome.
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Figure 1. Atypical melanocytic tumors. Kaplan-Meier curves for (A) OS and (B) PFS in the whole series.
Abbreviations: OS, overall survival; PFS, progression-free survival.
aNumber of patients at risk for an event.
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Figure 2. Unweighted and weighted Kaplan-Meier curves for (A, B) OS and (C, D) PFS according to sentinel node biopsy (performed or not
performed).
Abbreviations: OS, overall survival; PFS, progression-free survival; SNB, sentinel node biopsy.
aWeighted number of patients at risk for an event (rounded to the integer in the weighted analysis).
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Table 3. Results of Univariable Cox Model Analysis for Progression-Free Survival
Whole Series SNB Performed
HR (95% CI) P Value HR (95% CI) P Value
Agea
34 vs 26 y 5.28 (2.01–14.02) ,.001 5.18 (2.46–9.83) ,.001
#10 vs 11–20 y 1.83 (1.04–3.10) .060 1.83 (0.94–3.62) .101
#10 vs .20 y 3.43 (1.72–6.46) ,.001 3.86 (2.49–8.46) ,.001
11–20 vs .20 y 3.26 (1.54–6.17) ,.001 3.75 (2.37–8.28) ,.001
Sex .189 .081
Male vs female 1.47 (0.85–2.54) 1.88 (0.94–3.77)
Tumor site .142 .146
Head and neck vs lower limbs 0.81 (0.27–2.28) 0.86 (0.31–2.36)
Trunk vs lower limbs 2.28 (0.96–5.71) 2.39 (0.99–5.75)
Upper limbs vs lower limbs 1.43 (0.51–3.77) 1.45 (0.55–3.83)
Histologic subtype .139 .128
Spitzoid vs nonspitzoidb 0.82 (0.36–2.28) 0.48 (0.23–0.89)
Tumor thicknessa .106 .101
2.49 vs 2.20 mm 0.72 (0.51–1.02) 0.36 (0.14–0.93)
Ulcerationb .067 .189
Present vs absent 0.16 (0.00–1.09) 0.24 (0.00–1.66)
Mitosesa per mm2 ,.001 ,.001
4 vs 1 4.73 (2.18–8.50) 3.96 (2.05–7.60)
Mitoses at base of lesion ,.001 ,.001
Present vs absent 4.49 (2.04–7.86) 4.65 (2.34–8.08)
Tumor-infiltrating lymphocytes .927 .677
Brisk vs absent 1.09 (0.56–2.13) 1.14 (0.52–2.51)
Not brisk vs absent 1.14 (0.58–2.24) 0.77 (0.31–1.92)
Lymphovascular invasion ,.001 ,.001
Present vs absent 3.60 (1.96–6.87) 4.05 (2.19–8.06)
FISH test 6p25 .182 .179
Positive vs negative 1.90 (0.97–3.94) 1.74 (0.78–3.87)
FISH test 6q23/Cep6 .490 .917
Positive vs negative 1.64 (0.40–6.74) 0.90 (0.12–6.57)
FISH test 6p25/Cep6c .533 .283
Positive vs negative 0.46 (0.00–3.20) 0.51 (0.00–3.61)
FISH test 11q13 .176 .184
Positive vs negative 1.81 (0.76–4.05) 1.91 (0.88–4.22)
FISH test 9p21 ,.001 ,.001
Positive vs negative 4.53 (2.16–7.84) 4.67 (2.38–8.16)
FISH test 8q24c .618 .719
Positive vs negative 0.53 (0.00–3.68) 0.62 (0.00–4.41)
SNBd .024 —
Performed vs not performed 2.01 (1.10–3.67) —
Sentinel node status — .189
Positive vs negative — 2.01 (1.00–4.02)
P values were calculated using the Wald test.
Abbreviations: FISH, fluorescence in situ hybridization; HR, hazard ratio; SNB, sentinel node biopsy.
aModeled as restricted cubic spline. Reference values are third and first quartiles.
bNevoid, deep penetrating nevus, or atypical blue nevus.
cEstimated with Firth’s penalized model.
dInverse probability treatment weighted comparison.
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Our study also provides evidence that LVI was as-
sociated with shorter survival. We found that the tumor-
associated lymphatic network constituted a potential
criterion in the selection of high-risk patients who
should be candidates for careful follow-up. Another
investigation into the prognostic role of LVI in AMT
conducted by Abraham et al39 in a small number of
lesions related this parameter to a poorer prognosis.
Furthermore, our findings showed that the groups of
younger patients (aged ,10 years and 11–20 years) with
AMT had a longer survival. Spatz et al40 analyzed various
parameters, including age, to define a grading system for
risk stratification of atypical Spitz tumors. They found
that diagnosis at age .10 years carried a likelihood ratio
.1.50, so this variable was used for the grading system.
The low rate of local recurrences (1.7%) in our series
confirmed that wide surgical excision with 1-cmmargins
was adequate to control local recurrence. Ludgate et al,41
in another study of 67 patients with atypical Spitz tu-
mors, observed 1 local recurrence and recommended
1-cm excision margins to prevent local recurrences.
Finally, in our analysis, AMTs were classified into
specific risk categories based on the cytogenetic changes
determined by FISH. In the survival analysis, we found
that 9p21 loss was associated with a higher risk of distant
spread. Gerami et al20 evaluated 2 small subgroups of
high-risk melanocytic neoplasms in children—including
spitzoid melanomas, atypical Spitz tumors with chro-
mosomal copy number changes, and conventional
melanomas—and found that the presence of a homo-
zygous deletion of 9p21 and a positive SNB in atypical
Spitz tumors was associated with a higher risk of sys-
temic metastasis and death. Another analysis by Gerami
et al19 showed that also the presence of 6p25 and/or
11q13 gain was significantly associated with tumor
progression beyond the SN when compared with FISH-
negative tumors. In our series, 6p25 and 11q13 gains
were not associated with a higher risk of distant spread.
Additional techniques to assess molecular genetic al-
terations, such as comparative genomic hybridization,
next-generation sequencing, microRNA and mRNA
analysis, and mass spectrometric imaging, will help
improve the differential diagnosis and clinical man-
agement of AMTs in the near future.42
Conclusions
Our findings showed that age .20 years, MR $4, mi-
toses at the base of the lesion, LVI, and FISH evidence of
9p21 loss were all independent predictors of more ag-
gressive tumor behavior. SN status did not prove to be a
clear prognostic factor. Our retrospective analysis may
contribute to establishing a practical framework for
managing patients with AMTs in which clinical deci-
sions are supported by identifying at-risk patients who
may benefit from more frequent and longer-term fol-
low-up.
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eFigure 1. Kaplan-Meier curves for (A) OS and (B) PFS according to sentinel node biopsy result (positive or negative).
aNumber of patients at risk of an event.
Abbreviations: OS, overall survival; PFS, progression-free survival.
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eFigure 2. Unweighted and weighted Kaplan-Meier curves for (A, B) OS, and (C, D) PFS according to complete dissection (performed or not
performed).
aWeighted number of patients at risk of an event (rounded to the integer in the weighted analysis).
Abbreviations: OS, overall survival; PFS, progression-free survival.
JNCCN.org | Volume 18 Issue 10 | October 2020
Maurichi et al - 1
eTable 1. Clinicopathologic Characteristics of
Patients With AMT According to SN
Status
SN-Negative
n (%)
SN-Positive
n (%) SMD
Total 102 (73.4) 37 (26.6)
Age 0.137
#10 y 6 (5.9) 2 (5.4)
11–20 y 23 (22.5) 9 (24.3)
.20 y 73 (71.6) 26 (70.3)
Sex 0.425
Female 54 (52.9) 17 (45.9)
Male 48 (47.1) 20 (54.1)
Tumor site 0.328
Head and neck 34 (33.3) 10 (27.0)
Upper limbs 19 (18.6) 7 (18.9)
Trunk 12 (11.8) 4 (10.8)
Lower limbs 37 (36.3) 16 (43.2)
Histologic subtype 0.190
Spitzoid 24 (23.5) 10 (27.0)
Nonspitzoida 78 (76.5) 27 (73.0)
Tumor thickness, mm 0.471
Median (IQRE) 2.36 (2.25–2.51) 2.34 (2.15–2.40)
Ulceration 0.413
Absent 95 (93.1) 36 (97.3)
Present 7 (6.9) 1 (2.7)
Mitoses per mm2 1.946
Median (IQRE) 2 (1–2) 5 (4–6)
Mitosis at the base of the lesion 2.062
Absent 87 (85.3) 5 (13.5)
Present 15 (14.7) 32 (86.5)
Lymphovascular invasion 1.733
Absent 91 (89.2) 9 (24.3)
Present 11 (10.8) 28 (75.7)
Tumor-infiltrating lymphocytes 0.017
Absent 33 (32.3) 12 (32.4)
Brisk 37 (36.3) 13 (35.1)
Non brisk 32 (31.4) 12 (32.4)
FISH test 6p25 0.002
Negative 88 (86.3) 32 (86.5)
Positive 14 (13.7) 5 (13.5)
FISH test 6q23/Cep 6 0.023
Negative 99 (97.1) 36 (97.3)
Positive 3 (2.9) 1 (2.7)
FISH test 6p25/Cep 6
Negative 100 (98.0) 36 (97.3) 0.046
Positive 2 (2.0) 1 (2.7)
(continued)
eTable 1. Clinicopathologic Characteristics of
Patients With AMT According to SN
Status (cont.)
SN-Negative
n (%)
SN-Positive
n (%) SMD
FISH test 11q13 0.157
Negative 90 (88.2) 32 (86.5)
Positive 12 (11.8) 5 (13.5)
FISH test 9p21 1.587
Negative 72 (70.6) 20 (54.1)
Positive 30 (29.4) 17 (45.9)
FISH test 8q24 0.113
Negative 101 (99.0) 36 (97.3)
Positive 1 (1.0) 1 (2.7)
aNevoid, deep penetrating nevus, or atypical blue nevus.
Abbreviations: AMT, atypical melanocytic tumor; FISH, fluorescence in situ
hybridization; IQRE, interquartile range extremes; SMD, standardized mean
difference; SN, sentinel node.
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eTable 2. Clinicopathologic Characteristics of Patients With Positive SN According to CLND, Before and
After Propensity Score Weighting
Unweighted Statistics Weighted Statistics
No CLND
n (%)
CLND
n (%) SMD
No CLND
n (%)
CLND
n (%) SMD
Total 16 (43.2) 21 (56.8) 9.0 (50.8) 8.7 (49.2)
Age 1.413 1.637
#10 y 1 (6.3) 1 (4.8) 1.7 (19.0) 0 (0.3)
11–20 y 7 (43.7) 2 (9.5) 2.2 (24.6) 0.6 (6.8)
.20 y 8 (50.0) 18 (85.7) 5.1 (56.5) 8.1 (92.9)
Sex 0.048 0.057
Female 7 (43.7) 10 (47.6) 4.3 (47.6) 4.4 (50.5)
Male 9 (56.3) 11 (52.4) 4.7 (52.4) 4.3 (49.5)
Tumor site 0.966 0.874
Head and neck 5 (31.2) 5 (23.8) 1.1 (12.1) 1.2 (13.9)
Upper limbs 3 (18.8) 4 (19.0) 0.7 (7.6) 2.7 (32)
Trunk 0 (0) 4 (19.0) 3 (32.7) 1.8 (20.2)
Lower limbs 8 (50.0) 8 (38.1) 4.3 (47.6) 3 (34)
Histologic subtype 0.872 0.177
Spitzoid 2 (12.5) 8 (38.1) 1.3 (14.6) 1.5 (17.4)
Nonspitzoida 14 (87.5) 13 (61.9) 7.7 (85.4) 7.2 (82.6)
Tumor thickness, mm 0.047 0.035
Median (IQRE) 2.39 (2.20–2.40) 2.3 (2.12–2.36) 2.31 (2.08–2.40) 2.35 (2.17–2.38)
Ulceration ,0.001 ,0.001
Absent 16 (100) 20 (95.2) 9 (100) 8.2 (96.8)
Present 0 (0) 1 (4.8) 0 (0) 0.5 (3.2)
Mitoses per mm2 1.036 0.009
Median (IQRE) 6 (5–7) 5 (4–5) 5 (4.36–6.00) 5 (4.24–6.00)
Mitosis at the base of the lesion 0.791 0.107
Absent 0 (0) 5 (23.8) 0 (0) 0 (0.6)
Present 16 (100) 16 (76.2) 9 (100) 8.7 (99.4)
Lymphovascular invasion 0.512 0.050
Absent 2 (12.5) 7 (33.3) 1.3 (14.8) 1.1 (13.1)
Present 14 (87.5) 14 (66.7) 7.7 (85.2) 7.6 (86.9)
Tumor-infiltrating lymphocytes 0.675 0.739
Absent 5 (31.2) 7 (33.3) 2.4 (26.4) 4.1 (46.6)
Brisk 4 (25.0) 9 (42.9) 5.2 (58.2) 3.8 (44.7)
Non brisk 7 (43.8) 5 (23.8) 1.4 (15.4) 0.8 (8.7)
FISH test 6p25 0.183 0.410
Negative 14 (87.5) 18 (85.7) 5 (55.4) 5.3 (60.8)
Positive 2 (12.5) 3 (14.3) 4 (44.6) 3.4 (39.2)
FISH test 6q23/Cep 6 ,0.001 ,0.001
Negative 16 (100) 20 (95.2) 9 (100) 8.2 (96.8)
Positive 0 (0) 1 (4.8) 0 (0) 0.5 (3.2)
FISH test 6p25/Cep 6 ,0.001 ,0.001
Negative 16 (100) 20 (95.2) 9 (100) 8.2 (96.8)
Positive 0 (0) 1 (4.8) 0 (0) 0.5 (3.2)
(continued on next page)
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eTable 2. Clinicopathologic Characteristics of Patients With Positive SN According to CLND, Before and
After Propensity Score Weighting (cont.)
Unweighted Statistics Weighted Statistics
No CLND
n (%)
CLND
n (%) SMD
No CLND
n (%)
CLND
n (%) SMD
FISH test 11q13 0.183 0.410
Negative 14 (87.5) 18 (85.7) 5 (55.4) 5.3 (60.8)
Positive 2 (12.5) 3 (14.3) 4 (44.6) 3.4 (39.2)
FISH test 9p21 1.091 0.307
Negative 8 (50.0) 12 (57.1) 5.3 (58.4) 5.5 (62.4)
Positive 8 (50.0) 9 (42.9) 3.7 (41.6) 3.2 (37.6)
FISH test 8q24 ,0.001 ,0.001
Negative 16 (100) 20 (95.2) 9 (100) 8.2 (96.8)
Positive 0 (0) 1 (4.8) 0 (0) 0.5 (3.2)
aNevoid, deep penetrating nevus, or atypical blue nevus.
Abbreviations: CLND, completion lymph node dissection; FISH, fluorescence in sit hybridization; IQRE, interquartile range extremes; SMD, standardized mean
difference; SN, sentinel node.
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eAppendix 1. Statistical Methods
Survival Outcome Definitions
Overall survival (OS) was defined as the time from diagnosis to death from any cause; time was censored at the latest
follow-up for patients still alive. Progression-free survival (PFS)was defined as the timebetween tumor diagnosis and the
first event (regional nodal and/or in-transit metastases, distant metastases) or death, whichever occurred first; time was
censored at the date of last follow-up for alive and event-free patients.Median follow-upwas calculated with the reverse
Kaplan-Meier method using OS data.1
Inverse Probability Treatment Weighting and Balance Assessment
When a direct comparisonwas feasible (ie, when the compared groups did not consist of selected patients as in the SNB-
positive vs SNB-negative comparison), the curves were estimated using the Kaplan-Meier method and compared using
the log-rank test. Inverseprobability treatmentweighting (IPTW)2basedon thepropensity score (PS)methodwasused to
balance the comparison between groups. The covariates included in the logistic model for PS estimation were tumor
thickness, mitotic rate/mm2, ulceration, lymphovascular invasion (LVI), mitosis at the base of the lesion, spitzoid his-
tology, and 9p21 loss and 11q13 gain as determined by fluorescence in situ hybridization (FISH). The standardizedmean
difference (SMD)3 was used to evaluate the unbalanced and balanced clinicopathologic characteristics of patients with
atypical melanocytic tumors (AMT). SMDs $0.3 were considered indicative of a relevant between-group imbalance.
Association Analyses
We studied the binary association between all investigated covariates by evaluating the Spearman correlation co-
efficients, and the association between PFS and all investigated covariates by means of univariable Cox models.
Subgroup analyses were performed in patients who underwent sentinel node biopsy. We applied Firth’s penalized
method to obtain hazard ratio estimates in sparse samples.4 Mitotic rate, age, and tumor thickness were modeled as
continuous variables using a 3-knot restricted cubic spline to obtain a flexible fit.5 The small number of events
precluded statistical modeling on OS.
Variable Selection Method
The elastic net penalizationmethod is a combination of the ridge and lasso penalties, sharingwith the latter the ability to
set some coefficient estimates to zero but distributing the weight to more features, so that the elastic net tends to select
more features.
We considered a statistical test significant when the corresponding P value was ,.05. Statistical analyses were
performed using SAS version 9.2 (SAS Institute Inc) and R software 2018 (R Foundation for Statistical Computing).
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